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Abstract 
Toll-like receptor (TLR) proteins play key roles in immune responses against infection. Using 
TLR proteins, host can recognize the conserved molecular structures found in pathogens 
called pathogen-associated molecular patterns (PAMPs). At the same time, some TLRs are 
able to detect specific host molecules, such as high-mobility group box protein 1 (HMGB1) 
and heat shock proteins (hsp), and lead to inflammatory responses. Thus, it has been sug-
gested that TLRs are involved in the development of many pathogenic conditions. Recent 
advances in TLR-related research not only provide us with scientific information, but also 
show the therapeutic potential against diseases, such as autoimmune disease and cancer. In 
this mini review, we demonstrate how TLRs pathways could be involved in cancer devel-
opment and their therapeutic application, and discuss recent patentable subjects, in particular, 
that are targeting this unique pathway. 
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Introduction 
Toll-like receptors, a mammalian homologue of 
the drosophila toll protein, are the best-characterized 
family of pattern-recognition receptors (PRRs), which 
sense foreign material, so called pathogen-associated 
molecular patterns (PAMPs), derived from bacteria or 
virus. After activation of TLRs with their ligands ei-
ther directly or with help of accessory proteins such as 
CD14 and MD2 (in case of TLR2/4), cells evoke in-
flammatory response, coordinate the immune system 
in the whole organism, and finally protect the host 
from spreading massive pathogen after infection (1). 
So far, mammalian TLRs consist of at least 13 mem-
bers.  Each  TLR  contains  extracellular  domain  with 
leucine-rich repeats (LLR) motif, and these LLR com-
prise  a  binding  domain  for  recognition  of  their  re-
spective pathogens. It has been implicated that their 
cytoplasmic domains play a role in transducing sig-
naling to downstream pathways (2). 
Members  of  TLRs  are  well  conserved  in  both 
human and mouse, consisting of at least 11 members. 
Physiological ligands and functions of TLR1-9 have 
been  well  characterized  and  implicated  in  several 
cancers (Table 1). Ligands of each TLR are different; 
for example, TLR3, TLR7, TLR8, and TLR9 recognize 
nucleic acids derived from virus or bacteria whereas 
TLR2  recognizes  bacterial  lipoproteins,  lipotechoic 
acid and fungal zymosan. Lipopolysaccharide (LPS) 
from Gram negative bacteria cell wall is recognized by 
TLR4  and  bacterial  flagellin  activates  TLR5.TLRl1is 
present in mice, but not in human, and it has been 
known to recognize uropathogenic Escherichia coli (3), 
however, recent studies have identified a profilin-like 
protein from Toxoplasma gondiias a ligand  of  TLR11 
(4). No ligand has been identified for TLR10, 12 and 
13.  
TLR signaling has been extensively investigated 
in the last several years (5-7).There are two major TLR 
pathways; one is mediated by MyD88 adaptor pro-
teins, and the other is independent on MyD88. With 
exception  of  TLR3,  all  other  TLRs  commonly  use Int. J. Biol. Sci. 2010, 6 
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MyD88 as the downstream adopter protein. General-
ly, upon activation with their individual ligands, ac-
tivated  TLRs  recruit  MyD88,  leading  to  subsequent 
activation of the downstream targets, those including 
NF-B  (a  nuclear  factor  of  kappa  light  polypeptide 
gene enhancer in B-cells), mitogen-associated protein 
(MAP) kinase and interferon regulatory factors (IRFs). 
TLR3 and TLR4 induce NF-B activation through the 
TIR  domain-containing  adaptor  inducing  IFN- 
(TRIF)  to  activate  downstream  signaling. 
TLR-mediated activation of these molecules results in 
the production of antiviral type 1 interferon, proin-
flammatory  cytokines  and  chemokines  (Fig  1).  Rec-
ognition of PAMPs by TLR-expressing cells result in 
acute responses necessary to clear the pathogens in 
host. However, it has been also known that TLRs are 
involved  in  pathogenesis  of  autoimmune,  chronic 
inflammatory and infectious diseases (8, 9). The ac-
cumulating evidences indicate that multiple chronic 
inflammatory diseases caused by infection are asso-
ciated  with  TLRs,  leading  to  cancer  development 
(10-13), and that downstream molecules of TLR sig-
naling pathway are often involved in the tumorigenic 
inflammatory response. Previously, one group of re-
searchers  found  that  MyD88  is  required  in  a 
cell-autonomous  fashion  for  RAS-MAPK  signaling, 
leading to carcinogenesis (14). These results support 
an idea that MyD88 plays an important role not only 
in the pathway  of TLR-mediated inflammation, but 
also in RAS-MAPK signaling, cell-cycle control, and 
cell transformation. NF-B is also a well-known tran-
scriptional factor for innate and adaptive immunity 
and plays a crucial role in inflammation against in-
fectious molecules. Thus, NF-B signaling pathway is 
likely a link between chronic inflammation and tumor 
development (15), which are supported by observa-
tion that constitutively active NF-B is often found in 
a  number  of  human  malignancies  (16,  17).  Recent 
studies have directly demonstrated that NF-B plays a 
pivotal  role  in  TLRs-induced  tumorigenesis  when 
TLRs are activated by their ligand (15, 18). 
 
Table 1. TLR ligands and expression in various tumor cells and tissues. 
TLRs  Natural Ligand-origin  Expressing cancer cells and tissues  References 
TLR1  Triacyl Lipopeptides-Bacteria  Colon cancer  (47) 
Soluble factor-Neisseria meningitidis 
TLR2  Lipoprotein-various pathogens  Colon cancer  (48) 
Peptidoglycan-Gram+bacteria  Gastric cancer  (49) 
Lipoteichoic acid-Gram+bacteria  Hepatocellular carcinoma  (50) 
Zymosan-Fungi     
Heat-shock protein 70-host 
TLR3  Double stand RNA-Virus  Breast cancer   (33) 
Colon cancer  (47) 
Melanoma  (51) 
Hepatocellular carcinoma  (50) 
TLR4  Lipopolysaccharide-Gram negative bacteria  Breast cancer   (52) 
Envelope protein-MMTV  Colon cancer  (47) 
Oligosaccharides of hyaluronic acid-Host  Melanoma  (53) 
Heat-shock protein 60/70-Host  Gastric cancer  (54) 
  Lung cancer  (10) 
Hepatocellular carcinoma  (50) 
Ovarian cancer  (55) 
TLR5  Flagellin-Bacteria  Gastric cancer  (54) 
Cervical squamous cell carcinomas  (56) 
TLR6  Diacyl lipoproteins-mycoplasma  Hepatocellular carcinoma  (50) 
TLR7  Single-strand RNA-virus  Chronic lymphocytic leukemia  (57) 
TLR8  Single-strand RNA-virus     
TLR9  CpG-containing DNA-Bacteria and virus  Breast cancer   (58) 
Gastric cancer  (54) 
Hepatocellular carcinoma  (50) 
Cervical squamous cell carcinomas  (59) 
Glioma  (60) 
Prostate cancer  (61) 
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Fig 1. Diagram of TLR signaling pathways. TLRs localize to different subcellular compartments according to the 
molecular nature of the relevant ligands. TLR3, TLR7/8 and TLR9 are located at endolysosomal compartment and recog-
nized dsRNA or ssRNA or unmethylated CpG DNA, respectively. In contrast, TLR2, TLR4, TLR5, and TLR11 are mainly 
displayed on plasma membrane and recognize indicated ligands. TLR2/1 heterodimers respond to triacyl lipopeptide, while 
TLR2/6 heterodimers recognize diacyl lipopeptide. CD14 and MD-2 are accessory proteins required for LPS/TLR4 ligation. 
Following ligation with their respective ligands, TLRs recruit downstream adaptor molecules, such as MyD88 (all TLRs 
except TLR3) and TRIF (TLR3 and TLR4), to activate IRAK4, TRAF6 and IKK/TBK1. These sequentially activate signaling 
pathway of NF-B, p38 MAPK and JNK, leading to a series of specific cellular responses related to cell survival, proliferation 
and inflammation. IRF3 and 7 are also activated downstream of TLR3, 7, 8 and 9. These signaling mediate the production of 
type  1  interferon  and  antiviral  immune  responses.  MyD88:Myeloid  differentiation  primary-response  protein  88, 
IRAK:IL-1R-associated kinase, TRAM:TRIF-related adaptor molecules, TIRAP:TIR domain containing adaptor protein, 
TRAF:TNF receptor-associated factor, TAB:TGF- activated kinase 1/MAP3K7 binding protein, TAK:TGF--activated 
kinase,IKK:inhibitor of kappa light polypeptide gene enhancer in B-cells kinase, MIKK:mitogen-activated protein kinase 
kinase. 
 
 
Elevated expression of some TLRs has been re-
ported in many tumor cells, tissues or tumor cell lines 
(Table  1).  TLR4  is  over-expressed  in  human  and 
mouse inflammation-associated colorectal neoplasia, 
and TLR4-deficient mice are markedly protected from 
colon  carcinogenesis,  suggesting  that  expression  of 
TLRs on tumor cells promotes tumor progression di-
rectly or indirectly (19). Therefore, determination of 
distribution or tumor-specific expression of TLR and 
response of those cells to TLR ligand in specific types 
of tumor should be informative in terms of strategy 
for cancer therapy. 
As stated above, while expression of TLR often 
leads to tumor progression, TLR-mediated signaling 
also enhances the anti-cancer immunity and proteins 
in  TLR  signaling  pathway  are  often  considered  as Int. J. Biol. Sci. 2010, 6 
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important targets for therapy against cancer (20). Be-
cause tumor antigens are sometimes tolerant in cancer 
patients,  it  is  important  for  anti-cancer  therapy  to 
evoke  effective  immune  response  by  antigen  pre-
senting  cells  (APCs),  such  as  DCs,  against  antigens 
from tumor cells (10).  
Recent development in TLR-related application 
for cancer therapy include detection of different levels 
of  TLR  protein  and  their  activity  in  tumor  tissues, 
potential strategy of treatment using TLR agonist to 
induce immune function of specific cells against tu-
mor antigens, and development of new TLR agonist 
to  bust  anti-cancer  effects.  However,  because  some 
studies  have  described  that  tumorigenic  conditions 
are promoted by TLR-associated signaling, TLR an-
tagonists  should  be  also  considered  as  anti-cancer 
drug for specific cancer. 
TLR2 & TLR4 
It has been known that TLR expression in many 
tumors or cell lines was up-regulated (21). Also, in 
some tumor models, polymorphisms of TLR2 and 4 
have been known to influence the risk of cancer, im-
plicating that genetic variation in specific TLR may be 
associated with specific tumor progression (22).  
TLR4 has been known as indicative molecule for 
detection of predisposition to a cancer (23, 24). It is 
now  clear  that  anticancer  effect  by  Bacillus  Cal-
mette-Guerin  cell  wall  skeleton  (BCG-CWS)  is  me-
diated by both TLR2 and TLR4 (25).  Recently, Lionel 
et al described in vitro method of assessing the sensi-
tivity of a subject to a treatment of cancer, in particular 
to  a  chemotherapeutic  treatment  (26).  This  method 
involves detection of a mutated TLR4 nucleic acid as 
well as an abnormal TLR4 expression, being indica-
tive of a resistance to treatment for cancer.  They also 
claimed the method of determining a predisposition 
to a cancer or an increase probability of developing 
tumor in cancer patients. Their method comprised the 
detection of the presence of a mutated TLR4 sequence 
comprising a point mutation, preferably a single nuc-
leotide polymorphism (SNP) leading to the substitu-
tion  of  asparagine  by  glycine  at  position  299  or  of 
threonine by isoleucine at position 399. Finally, they 
describe  a  method  for  screening  compounds  useful 
for cancer therapy in a subject having a mutated TLR4 
through determining the ability of a test compound to 
modulate  the  expression  or  activity  of  TLR4  or  the 
relocalization  to  tumour  cell  plasma  membrane  of 
TLR4 ligands. 
Recent patent by Baylin et al claimed very inter-
esting diagnostic method for early detection of colon 
cancer  (27).  By  comparing  isogenic  cells  to  cancer 
cells, they found a series of genes with hypermeth-
lyated CpG island in cancer cells.  Among these genes, 
CpG  island  in  promoter  of  TLR2  was  hypermethy-
lated and we can predict TLR2 gene-silencing in pri-
mary cancer cells, suggesting TLR genes can be used 
to detect development of cancer, as well as pre-cancer.  
Additionally,  Hoon  et  al  suggested  some  me-
thods to detect the expression of TLR genes on mela-
noma cell (28). Based on information of expression, 
they claimed a method of modulating TLR gene ex-
pression using TLR agonists and a method of inhibit-
ing melanoma cell migration using TLR antagonists. 
Therefore, we can diagnoses predisposing condition 
and predict development of cancer in patients by de-
tection TLR2 & 4 expression and silencing in tissues 
through method as described above. These methods 
can provide parameters for exact diagnosis of tumor 
progress and information from above are important to 
develop new method for treatment against disease.  
TLR3  
As  described  above,  double-stranded  RNA  is 
recognized by TLR3 in normal cells or cancer cells. 
Several chemically synthesized dsRNAs (polyA-U or 
polyI-C) have been used in preclinical study and pre-
vious  data  showed  that  these  dsRNA  could  induce 
type 1 interferon production by blood mononuclear 
cells and that injection of these molecules enhances 
functions of the natural killer cells in vitro (29, 30). 
Also,  type  1  interferon  has  a  critical  role  in 
TLR3-mediated tumor suppression in mouse prostate 
tumors  models  (31).  Furthermore,  there  are  studies 
suggesting  that  TLR3  triggers  apoptosis  of  human 
prostate cells and breast cancer cells (32, 33). Because 
apoptosis may be a potent mechanism of eliminating 
tumor cells, these previous results suggest that TLR3 
or TLR3 ligands may be very useful tool for cancer 
therapy. 
Recently, one group developed a method to en-
hance  the  therapeutic  efficacy  of  dsRNA  (34).  They 
claimed  methods  of  treating  cancers  using  TLR3 
agonist (polyA-U and polyI-C), by assessing the ex-
pression of a TLR3 receptor by cancer cells. Their in-
vention is composed of two parts; one is the detection 
of TLR3 expression in cancer cells by specific TLR3 
antibody (or fragment of antibody) and TLR3-specific 
primer (or probe). Secondary, they invented specific 
method to treat cancer patient who have TLR3 posi-
tive cancer cell or tissue. They showed that overex-
pression of TLR3 in tumor cells are observed in 10% of 
samples and these TLR3 positive breast cancer were 
found to well respond to polyA-U or polyI-C com-
pared  to  TLR3  negative  cells.  Thus,  these  patients 
could benefit from the TLR3 agonist administration.  Int. J. Biol. Sci. 2010, 6 
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TLR5 
TLR5  recognizes  flagellin  and  is  mainly  ex-
pressed on antigen presenting cells (APCs), such as 
monocytes and DCs. Upon ligand-TLR5 interaction, 
flagellin  evokes  a  series  of  immunomodulatory  re-
sponse in these cells (35, 36). Therefore, flagellin has 
been  used  as  adjuvant  that  is  effective  in  inducing 
innate immune response by APCs against tumor an-
tigens (37). In this patent, they found that flagellin can 
inhibit tolerance on tumor antigens after administra-
tion in combination with tolerogenic tumor antigens. 
This  effect  of  flagellin  may  be  due  to  induction  of 
IL-12  from  APCs,  while  keeping  IL-10  levels  low. 
They used flagellin-expressing cell and tumor cell as 
an adjuvant, wherein all cells have been lethally irra-
diated.  Recently,  one  group  designed  and  tested  a 
series of engineered flagellin derivates for NF-B ac-
tivation in vitro (38). They showed that most potent 
NF-B activator, designated CBLB502, have the radi-
oprotective  effect  in  mouse  model.  The  injection  of 
CBLB502 before lethal dose of total-body -irradiation 
(IR)  protected  mice  from  both  gastrointestinal  and 
hematopoietic acute radiation syndromes, and led to 
improved survival. In contrast to normal tissues, this 
TLR5  ligand  didn’t  change  the  radiosensitivity  of 
mouse  tumor,  implying  that  TLR5  ligand  may  be 
valuable adjuvants for cancer radiotherapy and rela-
tively  safe  protector  for  normal  cells  against  high 
dose-radiation during IR. Although flagellin-elicited 
radioprotection  required  the  TLR  signaling  adaptor 
MyD88,  as  well  as  TLR5  (39),  the  underlying  me-
chanism remains unclear. 
TLR7 & TLR8 
Imidazoquinoline  compounds  are  well-known 
TLR7/8 agonists with strong local activity for innate 
immunity in viral infection and cancer. Synthetic im-
idazoquinoline compounds have been used as a po-
tent  adjuvant  for  eliciting  T-cell  responses  to  intra-
cellular pathogens and model protein antigens (40). 
For example, AldaraTM (3M; imiquimod) is formulated 
as a cream for the treatment of superficial basal cell 
carcinoma, HPV infection (41). Attenuated mycobac-
terial antigen has been known as good candidate to 
set up therapy against HPV-related disease including 
cancer, but treatment for patients remains unsatisfac-
tory in its efficacy and side effects.   
Romagne et al have invented new TLR7 agonists 
and they have set up the method useful for treating a 
carcinoma (e.g. Bladder cancer) or viral infection (42). 
They synthesized new imidazoquinoline compounds 
and screened to find strong gamma delta T cell acti-
vator. Because gamma delta T cell is an important T 
cell subtype for innate immunity against cancers, they 
described immunization with mycobacterium antigen 
when used in combination therapy with TLR7 could 
be  more  effective  than  when  used  only  antigen. 
Therefore, they claimed this method is effective some 
diseases, such as a bladder cancer, a skin tumor or an 
HPV infection.  
TLR9 
As  described  above,  unmethylated  CpG  oligo-
nucleotides are generally detected by TLR9, leading to 
DC activation for innate and adaptive immunity. Be-
cause  tumor  can  escape  from  immune  surveillance 
system  by  interfering  DC  function  or  by  failing  to 
provide the necessary activation signals (43), Vicari et 
al have invented method for the modulation of the 
immune response through the manipulation of DCs 
using combined treatment with CpG oligodeoxynuc-
leotides (CpG ODNs) and IL-10 antagonists (44). IL-10 
secreted  from  tumor  cells  has  been  well  known  as 
strong  regulator  of  DC  function  (45).  Indeed,  IL-10 
induces T cell unresponsiveness and down-regulates 
innate immunity against tumor through the inhibition 
of IL-12 production (46). Furthermore, combined ad-
ministration of an IL-10 antagonist and a TLR9 agon-
ist is one of candidates for cancer treatment. There-
fore, their invention provides a method of treatment 
against cancer comprising administering to a patient 
with a series of a tumor-derived DC inhibitory factor 
antagonist (e.g. IL-10 signaling blocker) in combina-
tion with CpG ODNs as TLR9 agonist.  
Current and Future Developments 
TLRs have been implicated as a family of pro-
teins which are involved in induction of innate im-
mune  response  against  microbial  insult  from  sur-
rounding,  such  as  bacteria  and  virus.  Today,  a  re-
search between innate immunity and cancer is draw-
ing a lot of attention from investigators, and this study 
actually  provides  critical  information  for  develop-
ment of therapeutic strategies against cancer. Recent 
studies  and  patents  showed  TLR  expression  profile 
could be one of guidelines for diagnosis of specific 
cancer. Using TLR agonist or antagonist in combina-
tion with antigen isolated from tumor, we can antic-
ipate  increasing  effect  of  vaccination  and  evoking 
specific  innate  immunity  against  cancer.  Although 
TLR  can  mediate  host  innate  immune  system, 
over-expression  of  TLRs  has  been  paradoxically 
found in many tumor cases. Furthermore, it has been 
demonstrated that TLR-mediated signaling promotes 
tumor growth, and escape of tumor cells from host 
immune  system  has  been  observed  in  some  cancer 
models. These studies and observation strongly sug-Int. J. Biol. Sci. 2010, 6 
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gest that biological outcomes induced by high levels 
of the protein are determined by both inter- and in-
tra-cellular environment. Although recent issues have 
continuously claimed that specific TLR or signaling 
molecules in TLR pathway are involved in pathoge-
nesis  of  cancers,  choices  of  use  of either  agonist  or 
antagonist for TLR in the context of therapy could not 
be decided immediately. The study of TLRs is still in 
early  stage,  so  we  need  to  explore  more  detailed 
function  of  each  TLR  in  different  types  of  cancer. 
Without that information, one would not be able to 
develop therapeutic strategies using TLR pathway. 
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